Deltex Medical Group plc New Chief Executive

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect.

Mr. Phillips recently approached Deltex’s Chairman indicating that he had concluded that it was now time for a change in leadership to guide the Group through its next stage of development. After leading the Group for a number of years, he felt that Deltex was now well-positioned following the successful fund raising in February 2018, recent cost reductions, the launch of the TrueVue platform, the recently published FEDORA study and repositioning of both its core clinical and health economic propositions.

Andy Mears, who is currently the Managing Director of Deltex Medical Limited, the Group’s principal operating subsidiary, has been appointed as the Group’s new Chief Executive and a Director of the Company. The Board appointment is subject to completion of certain regulatory formalities.

Mr. Mears, aged 49, started at Deltex Medical Group plc as an engineer in 1989 and has worked in a number of operational roles in the Group. Within his current role, he has responsibility for international sales and Deltex’s Key Opinion Leader development programmes.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change

    Deltex Medical Group Plc

    FEDORA Study “Take-Homes” for clinicians

    Clinician-led disseminator of medical news, TopMedTalk has reviewed the landmark FEDORA study into Goal-Directed Haemodynamic Therapy (GDHT). Reinforcing the conclusions from meta-analysis of 70 other studies, FEDORA supports the use of Oesophageal Doppler to derive clinical parameters that